$BMRN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in BIOMARIN PHARMACEUTICAL INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in BIOMARIN PHARMACEUTICAL INC. Get notifications about new insider transactions in BIOMARIN PHARMACEUTICAL INC for free.
Page: < prev 1 2 3 4 5 6 ... 34 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 15 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Option Exercise | M | 67.81 | 13,810 | 936,456 | 75,716 | |
| Jul 15 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Option Exercise | M | 67.81 | 224 | 15,189 | 1,250 | |
| Jul 15 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Sell | S | 130.00 | 23,011 | 2,991,430 | 102,995 | 126 K to 103 K (-18.26 %) |
| Jul 15 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Buy | M | 63.10 | 8,977 | 566,449 | 126,006 | 117 K to 126 K (+7.67 %) |
| Jul 15 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Buy | M | 67.81 | 13,810 | 936,456 | 117,029 | 103.2 K to 117 K (+13.38 %) |
| Jul 15 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Buy | M | 67.81 | 224 | 15,189 | 103,219 | 103 K to 103.2 K (+0.22 %) |
| Jul 15 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Grant | A | 62.59 | 339 | 21,217 | 102,995 | 102.7 K to 103 K (+0.33 %) |
| Jun 30 2020 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Option Exercise | A | 122.18 | 13,230 | 1,616,441 | 13,230 | |
| Jun 30 2020 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Grant | A | 0.00 | 4,640 | 0 | 29,744 | 25.1 K to 29.7 K (+18.48 %) |
| Jun 30 2020 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Grant | A | 62.59 | 323 | 20,215 | 25,104 | 24.8 K to 25.1 K (+1.30 %) |
| Jun 30 2020 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Option Exercise | A | 122.18 | 13,230 | 1,616,441 | 13,230 | |
| Jun 30 2020 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Grant | A | 0.00 | 4,640 | 0 | 29,744 | 25.1 K to 29.7 K (+18.48 %) |
| Jun 30 2020 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Grant | A | 62.59 | 323 | 20,215 | 25,104 | 24.8 K to 25.1 K (+1.30 %) |
| Jun 30 2020 | BMRN | BIOMARIN PHARMACEU ... | Dere Willard H | Director | Sell | S | 123.61 | 4,430 | 547,592 | 13,290 | 17.7 K to 13.3 K (-25.00 %) |
| Jun 23 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Option Exercise | M | 63.10 | 15,000 | 946,500 | 15,700 | |
| Jun 23 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 124.00 | 15,000 | 1,860,000 | 63,402 | 78.4 K to 63.4 K (-19.13 %) |
| Jun 23 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Buy | M | 63.10 | 15,000 | 946,500 | 78,402 | 63.4 K to 78.4 K (+23.66 %) |
| Jun 23 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 62.59 | 338 | 21,154 | 63,402 | 63.1 K to 63.4 K (+0.54 %) |
| Jun 09 2020 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Sell | S | 107.46 | 4,430 | 476,048 | 18,850 | 23.3 K to 18.9 K (-19.03 %) |
| May 29 2020 | BMRN | BIOMARIN PHARMACEU ... | Slamon Dennis | Director | Grant | A | 0.00 | 4,300 | 0 | 22,915 | 18.6 K to 22.9 K (+23.10 %) |
| May 29 2020 | BMRN | BIOMARIN PHARMACEU ... | PYOTT DAVID E I | Director | Grant | A | 0.00 | 4,300 | 0 | 17,940 | 13.6 K to 17.9 K (+31.52 %) |
| May 29 2020 | BMRN | BIOMARIN PHARMACEU ... | MEIER RICHARD A | Director | Grant | A | 0.00 | 4,300 | 0 | 84,340 | 80 K to 84.3 K (+5.37 %) |
| May 29 2020 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Grant | A | 0.00 | 4,300 | 0 | 23,280 | 19 K to 23.3 K (+22.66 %) |
| May 29 2020 | BMRN | BIOMARIN PHARMACEU ... | HOMBACH ROBERT J. | Director | Grant | A | 0.00 | 4,300 | 0 | 16,210 | 11.9 K to 16.2 K (+36.10 %) |
| May 29 2020 | BMRN | BIOMARIN PHARMACEU ... | HERON ELAINE J | Director | Grant | A | 0.00 | 4,300 | 0 | 51,968 | 47.7 K to 52 K (+9.02 %) |
| May 29 2020 | BMRN | BIOMARIN PHARMACEU ... | HERON ELAINE J | Director | Grant | A | 0.00 | 4,300 | 0 | 51,968 | 47.7 K to 52 K (+9.02 %) |
| May 29 2020 | BMRN | BIOMARIN PHARMACEU ... | GREY MICHAEL G | Director | Grant | A | 0.00 | 4,300 | 0 | 42,840 | 38.5 K to 42.8 K (+11.16 %) |
| May 29 2020 | BMRN | BIOMARIN PHARMACEU ... | Dere Willard H | Director | Grant | A | 0.00 | 4,300 | 0 | 17,720 | 13.4 K to 17.7 K (+32.04 %) |
| May 29 2020 | BMRN | BIOMARIN PHARMACEU ... | ANDERSON ELIZABETH M | Director | Grant | A | 0.00 | 4,300 | 0 | 8,790 | 4.5 K to 8.8 K (+95.77 %) |
| May 12 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 21.51 | 20,000 | 430,200 | 0 | |
| May 12 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 91.72 | 20,000 | 1,834,400 | 298,552 | 318.6 K to 298.6 K (-6.28 %) |
| May 12 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 21.51 | 20,000 | 430,200 | 318,552 | 298.6 K to 318.6 K (+6.70 %) |
| May 06 2020 | BMRN | BIOMARIN PHARMACEU ... | Guyer Charles Greg | EVP, Chief Technica ... | Option Exercise | A | 90.36 | 64,150 | 5,796,594 | 64,150 | |
| May 06 2020 | BMRN | BIOMARIN PHARMACEU ... | Guyer Charles Greg | EVP, Chief Technica ... | Grant | A | 0.00 | 35,040 | 0 | 35,040 | 0 to 35 K |
| May 05 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 21.51 | 5,000 | 107,550 | 20,000 | |
| May 05 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 21.51 | 4,000 | 86,040 | 25,000 | |
| May 05 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 88.00 | 5,000 | 440,000 | 298,552 | 303.6 K to 298.6 K (-1.65 %) |
| May 05 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 21.51 | 5,000 | 107,550 | 303,552 | 298.6 K to 303.6 K (+1.67 %) |
| May 05 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 89.38 | 4,000 | 357,520 | 298,552 | 302.6 K to 298.6 K (-1.32 %) |
| May 05 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 21.51 | 4,000 | 86,040 | 302,552 | 298.6 K to 302.6 K (+1.34 %) |
| May 05 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Grant | A | 62.59 | 339 | 21,217 | 298,552 | 298.2 K to 298.6 K (+0.11 %) |
| May 04 2020 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Sell | S | 89.38 | 12,504 | 1,117,608 | 65,677 | 78.2 K to 65.7 K (-15.99 %) |
| May 04 2020 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Grant | A | 62.59 | 339 | 21,217 | 78,181 | 77.8 K to 78.2 K (+0.44 %) |
| May 04 2020 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Sell | S | 89.38 | 12,504 | 1,117,608 | 65,677 | 78.2 K to 65.7 K (-15.99 %) |
| May 04 2020 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Grant | A | 62.59 | 339 | 21,217 | 78,181 | 77.8 K to 78.2 K (+0.44 %) |
| Apr 29 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 21.51 | 20,000 | 430,200 | 29,000 | |
| Apr 29 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 21.51 | 20,000 | 430,200 | 49,000 | |
| Apr 29 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 97.58 | 20,000 | 1,951,600 | 298,213 | 318.2 K to 298.2 K (-6.29 %) |
| Apr 29 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 21.51 | 20,000 | 430,200 | 318,213 | 298.2 K to 318.2 K (+6.71 %) |
| Apr 29 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 97.73 | 20,000 | 1,954,600 | 298,213 | 318.2 K to 298.2 K (-6.29 %) |
| Apr 29 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 21.51 | 20,000 | 430,200 | 318,213 | 298.2 K to 318.2 K (+6.71 %) |
| Apr 28 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Sell | S | 97.32 | 2,680 | 260,813 | 102,656 | 105.3 K to 102.7 K (-2.54 %) |
| Apr 28 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Sell | S | 96.85 | 3,678 | 356,211 | 105,336 | 109 K to 105.3 K (-3.37 %) |
| Apr 28 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Sell | S | 95.34 | 13,642 | 1,300,593 | 109,014 | 122.7 K to 109 K (-11.12 %) |
| Apr 22 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Sell | S | 90.00 | 17,213 | 1,549,170 | 122,656 | 139.9 K to 122.7 K (-12.31 %) |
| Apr 13 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 21.51 | 10,000 | 215,100 | 69,000 | |
| Apr 13 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 79.06 | 10,000 | 790,600 | 298,213 | 308.2 K to 298.2 K (-3.24 %) |
| Apr 13 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 21.51 | 10,000 | 215,100 | 308,213 | 298.2 K to 308.2 K (+3.35 %) |
| Apr 09 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 79.98 | 2,407 | 192,512 | 63,064 | 65.5 K to 63.1 K (-3.68 %) |
| Apr 09 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 79.98 | 2,407 | 192,512 | 63,064 | 65.5 K to 63.1 K (-3.68 %) |
| Apr 08 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 26.49 | 1,000 | 26,490 | 139,513 | |
| Apr 08 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 26.49 | 1,000 | 26,490 | 298,213 | 297.2 K to 298.2 K (+0.34 %) |
| Apr 08 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 26.49 | 1,000 | 26,490 | 139,513 | |
| Apr 08 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 26.49 | 1,000 | 26,490 | 298,213 | 297.2 K to 298.2 K (+0.34 %) |
| Apr 02 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 82.00 | 1,537 | 126,034 | 65,471 | 67 K to 65.5 K (-2.29 %) |
| Mar 26 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 78.47 | 1,618 | 126,964 | 67,008 | 68.6 K to 67 K (-2.36 %) |
| Mar 26 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 74.36 | 2,041 | 151,769 | 68,626 | 70.7 K to 68.6 K (-2.89 %) |
| Mar 24 2020 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | President, Global M ... | Payment of Exercise | F | 73.05 | 3,501 | 255,748 | 117,138 | 120.6 K to 117.1 K (-2.90 %) |
| Mar 24 2020 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Payment of Exercise | F | 73.05 | 3,309 | 241,722 | 77,842 | 81.2 K to 77.8 K (-4.08 %) |
| Mar 24 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Payment of Exercise | F | 73.05 | 5,836 | 426,320 | 139,869 | 145.7 K to 139.9 K (-4.01 %) |
| Mar 24 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Payment of Exercise | F | 73.05 | 13,128 | 959,000 | 297,213 | 310.3 K to 297.2 K (-4.23 %) |
| Mar 24 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 73.05 | 3,599 | 262,907 | 70,667 | 74.3 K to 70.7 K (-4.85 %) |
| Mar 24 2020 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Acting CFO | Payment of Exercise | F | 73.05 | 414 | 30,243 | 24,781 | 25.2 K to 24.8 K (-1.64 %) |
| Mar 18 2020 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Option Exercise | M | 21.51 | 3,750 | 80,663 | 0 | |
| Mar 18 2020 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Sell | S | 75.39 | 3,750 | 282,713 | 18,980 | 22.7 K to 19 K (-16.50 %) |
| Mar 18 2020 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Buy | M | 21.51 | 3,750 | 80,663 | 22,730 | 19 K to 22.7 K (+19.76 %) |
| Mar 18 2020 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Sell | S | 76.52 | 4,610 | 352,757 | 18,980 | 23.6 K to 19 K (-19.54 %) |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Acting CFO | Option Exercise | A | 73.82 | 9,600 | 708,672 | 9,600 | |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Acting CFO | Grant | A | 0.00 | 6,730 | 0 | 25,195 | 18.5 K to 25.2 K (+36.45 %) |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Acting CFO | Payment of Exercise | F | 84.50 | 1,303 | 110,104 | 18,465 | 19.8 K to 18.5 K (-6.59 %) |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Option Exercise | A | 73.82 | 28,790 | 2,125,278 | 28,790 | |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Grant | A | 0.00 | 10,100 | 0 | 81,151 | 71.1 K to 81.2 K (+14.22 %) |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Payment of Exercise | F | 84.50 | 7,244 | 612,118 | 71,051 | 78.3 K to 71.1 K (-9.25 %) |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Option Exercise | A | 73.82 | 51,970 | 3,836,425 | 51,970 | |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Grant | A | 0.00 | 18,220 | 0 | 145,705 | 127.5 K to 145.7 K (+14.29 %) |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Payment of Exercise | F | 84.50 | 10,496 | 886,912 | 127,485 | 138 K to 127.5 K (-7.61 %) |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | President, Global M ... | Option Exercise | A | 73.82 | 30,390 | 2,243,390 | 30,390 | |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | President, Global M ... | Grant | A | 0.00 | 10,660 | 0 | 120,639 | 110 K to 120.6 K (+9.69 %) |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | President, Global M ... | Payment of Exercise | F | 84.50 | 7,600 | 642,200 | 109,979 | 117.6 K to 110 K (-6.46 %) |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | A | 73.82 | 127,920 | 9,443,054 | 127,920 | |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Grant | A | 0.00 | 44,850 | 0 | 310,341 | 265.5 K to 310.3 K (+16.89 %) |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Payment of Exercise | F | 84.50 | 30,952 | 2,615,444 | 265,491 | 296.4 K to 265.5 K (-10.44 %) |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Option Exercise | A | 73.82 | 29,590 | 2,184,334 | 29,590 | |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 0.00 | 10,380 | 0 | 74,266 | 63.9 K to 74.3 K (+16.25 %) |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 84.50 | 7,644 | 645,918 | 63,886 | 71.5 K to 63.9 K (-10.69 %) |
| Mar 11 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 21.51 | 10,000 | 215,100 | 79,000 | |
| Mar 11 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 89.52 | 10,000 | 895,200 | 296,443 | 306.4 K to 296.4 K (-3.26 %) |
| Mar 11 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 21.51 | 10,000 | 215,100 | 306,443 | 296.4 K to 306.4 K (+3.37 %) |
| Mar 11 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | L | 94.39 | 30 | 2,832 | 296,443 | 296.4 K to 296.4 K (+0.01 %) |
| Mar 04 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Grant | A | 0.00 | 13,136 | 0 | 137,981 | 124.8 K to 138 K (+10.52 %) |
| Mar 04 2020 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Grant | A | 0.00 | 9,586 | 0 | 78,295 | 68.7 K to 78.3 K (+13.95 %) |
| Mar 04 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Grant | A | 0.00 | 35,580 | 0 | 296,413 | 260.8 K to 296.4 K (+13.64 %) |
| Mar 04 2020 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | President, Global M ... | Grant | A | 0.00 | 9,852 | 0 | 117,579 | 107.7 K to 117.6 K (+9.15 %) |
| Mar 04 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 0.00 | 9,586 | 0 | 71,530 | 61.9 K to 71.5 K (+15.48 %) |
| Feb 05 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 21.51 | 10,000 | 215,100 | 89,000 | |
| Feb 05 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 83.50 | 10,000 | 835,000 | 328,530 | 338.5 K to 328.5 K (-2.95 %) |
| Feb 05 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 21.51 | 10,000 | 215,100 | 338,530 | 328.5 K to 338.5 K (+3.04 %) |
| Feb 04 2020 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Acting CFO | Grant | A | 0.00 | 5,800 | 0 | 19,768 | 14 K to 19.8 K (+41.52 %) |
| Feb 04 2020 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Acting CFO | Grant | A | 62.23 | 9 | 560 | 13,968 | 14 K to 14 K (+0.06 %) |
| Feb 03 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 21.51 | 1,000 | 21,510 | 99,000 | |
| Feb 03 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 21.51 | 1,000 | 21,510 | 328,530 | 327.5 K to 328.5 K (+0.31 %) |
| Jan 16 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 21.51 | 8,000 | 172,080 | 100,000 | |
| Jan 16 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 87.95 | 8,000 | 703,600 | 327,530 | 335.5 K to 327.5 K (-2.38 %) |
| Jan 16 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 21.51 | 8,000 | 172,080 | 335,530 | 327.5 K to 335.5 K (+2.44 %) |
| Jan 16 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 21.51 | 8,000 | 172,080 | 100,000 | |
| Jan 16 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 87.95 | 8,000 | 703,600 | 327,530 | 335.5 K to 327.5 K (-2.38 %) |
| Jan 16 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 21.51 | 8,000 | 172,080 | 335,530 | 327.5 K to 335.5 K (+2.44 %) |
| Jan 09 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 21.51 | 4,000 | 86,040 | 108,000 | |
| Jan 09 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 21.51 | 3,000 | 64,530 | 112,000 | |
| Jan 09 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 84.92 | 4,000 | 339,680 | 327,530 | 331.5 K to 327.5 K (-1.21 %) |
| Jan 09 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 21.51 | 4,000 | 86,040 | 331,530 | 327.5 K to 331.5 K (+1.22 %) |
| Jan 09 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 21.51 | 4,000 | 86,040 | 108,000 | |
| Jan 09 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 84.46 | 3,000 | 253,380 | 327,530 | 330.5 K to 327.5 K (-0.91 %) |
| Jan 09 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 21.51 | 3,000 | 64,530 | 112,000 | |
| Jan 09 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 21.51 | 3,000 | 64,530 | 330,530 | 327.5 K to 330.5 K (+0.92 %) |
| Jan 09 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 84.92 | 4,000 | 339,680 | 327,530 | 331.5 K to 327.5 K (-1.21 %) |
| Jan 09 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 21.51 | 4,000 | 86,040 | 331,530 | 327.5 K to 331.5 K (+1.22 %) |
| Jan 09 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 84.46 | 3,000 | 253,380 | 327,530 | 330.5 K to 327.5 K (-0.91 %) |
| Jan 09 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 21.51 | 3,000 | 64,530 | 330,530 | 327.5 K to 330.5 K (+0.92 %) |
| Dec 30 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 21.51 | 5,000 | 107,550 | 115,000 | |
| Dec 30 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 21.51 | 3,000 | 64,530 | 120,000 | |
| Dec 30 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Gift | G | 0.00 | 630 | 0 | 180,261 | 180.9 K to 180.3 K (-0.35 %) |
| Dec 30 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 86.16 | 5,000 | 430,800 | 327,530 | 332.5 K to 327.5 K (-1.50 %) |
| Dec 30 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 21.51 | 5,000 | 107,550 | 332,530 | 327.5 K to 332.5 K (+1.53 %) |
| Dec 30 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 86.43 | 3,000 | 259,290 | 327,530 | 330.5 K to 327.5 K (-0.91 %) |
| Dec 30 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 21.51 | 3,000 | 64,530 | 330,530 | 327.5 K to 330.5 K (+0.92 %) |
| Dec 30 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 21.51 | 5,000 | 107,550 | 115,000 | |
| Dec 30 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 21.51 | 3,000 | 64,530 | 120,000 | |
| Dec 30 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Gift | G | 0.00 | 630 | 0 | 180,261 | 180.9 K to 180.3 K (-0.35 %) |
| Dec 30 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 86.16 | 5,000 | 430,800 | 327,530 | 332.5 K to 327.5 K (-1.50 %) |
| Dec 30 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 21.51 | 5,000 | 107,550 | 332,530 | 327.5 K to 332.5 K (+1.53 %) |
| Dec 30 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 86.43 | 3,000 | 259,290 | 327,530 | 330.5 K to 327.5 K (-0.91 %) |
| Dec 30 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 21.51 | 3,000 | 64,530 | 330,530 | 327.5 K to 330.5 K (+0.92 %) |
| Dec 19 2019 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Option Exercise | M | 21.51 | 3,750 | 80,663 | 3,750 | |
| Dec 19 2019 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Sell | S | 83.36 | 3,750 | 312,600 | 23,590 | 27.3 K to 23.6 K (-13.72 %) |
| Dec 19 2019 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Buy | M | 21.51 | 3,750 | 80,663 | 27,340 | 23.6 K to 27.3 K (+15.90 %) |
| Nov 27 2019 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Sell | S | 79.66 | 3,190 | 254,115 | 68,709 | 71.9 K to 68.7 K (-4.44 %) |
| Nov 26 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 21.51 | 4,000 | 86,040 | 123,000 | |
| Nov 26 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 21.51 | 6,000 | 129,060 | 127,000 | |
| Nov 26 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 77.60 | 10,000 | 776,000 | 327,080 | 337.1 K to 327.1 K (-2.97 %) |